These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 25583246)

  • 1. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.
    Cohen SM; Tsien RW; Goff DC; Halassa MM
    Schizophr Res; 2015 Sep; 167(1-3):98-107. PubMed ID: 25583246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The origin of NMDA receptor hypofunction in schizophrenia.
    Nakazawa K; Sapkota K
    Pharmacol Ther; 2020 Jan; 205():107426. PubMed ID: 31629007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMDAR hypofunction attenuates driver inputs in higher order thalamic nuclei: an alternative view.
    Vukadinovic Z
    Schizophr Res; 2015 Aug; 166(1-3):341-2. PubMed ID: 25868931
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased excitation-inhibition balance and loss of GABAergic synapses in the serine racemase knockout model of NMDA receptor hypofunction.
    Jami SA; Cameron S; Wong JM; Daly ER; McAllister AK; Gray JA
    J Neurophysiol; 2021 Jul; 126(1):11-27. PubMed ID: 34038186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to: NMDA hypofunction attenuates driver inputs in higher order thalamic nuclei: An alternative view.
    Cohen SM; Halassa MM
    Schizophr Res; 2015 Aug; 166(1-3):343-4. PubMed ID: 25956632
    [No Abstract]   [Full Text] [Related]  

  • 6. NMDA receptor function in inhibitory neurons.
    Booker SA; Wyllie DJA
    Neuropharmacology; 2021 Sep; 196():108609. PubMed ID: 34000273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis.
    Hardingham GE; Do KQ
    Nat Rev Neurosci; 2016 Feb; 17(2):125-34. PubMed ID: 26763624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GABAergic interneuron origin of schizophrenia pathophysiology.
    Nakazawa K; Zsiros V; Jiang Z; Nakao K; Kolata S; Zhang S; Belforte JE
    Neuropharmacology; 2012 Mar; 62(3):1574-83. PubMed ID: 21277876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D-Aspartate: An endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia.
    Errico F; Mothet JP; Usiello A
    J Pharm Biomed Anal; 2015 Dec; 116():7-17. PubMed ID: 25868730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia.
    Jadi MP; Behrens MM; Sejnowski TJ
    Biol Psychiatry; 2016 May; 79(9):716-726. PubMed ID: 26281716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMDA receptor activation enhances inhibitory GABAergic transmission onto hippocampal pyramidal neurons via presynaptic and postsynaptic mechanisms.
    Xue JG; Masuoka T; Gong XD; Chen KS; Yanagawa Y; Law SK; Konishi S
    J Neurophysiol; 2011 Jun; 105(6):2897-906. PubMed ID: 21471392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenia: Basic and Clinical.
    Coyle JT
    Adv Neurobiol; 2017; 15():255-280. PubMed ID: 28674984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Basis of GABA Hypofunction in Adolescent Schizophrenia-Like Animals.
    Wang X; Hu Y; Liu W; Ma Y; Chen X; Xue T; Cui D
    Neural Plast; 2021; 2021():9983438. PubMed ID: 33936193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.
    Balu DT
    Adv Pharmacol; 2016; 76():351-82. PubMed ID: 27288082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.
    Snyder MA; Gao WJ
    Schizophr Res; 2020 Mar; 217():60-70. PubMed ID: 30979669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression.
    Anderson G; Maes M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():5-19. PubMed ID: 22800757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
    Yang CR; Chen L
    Neuroscientist; 2005 Oct; 11(5):452-70. PubMed ID: 16151046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.
    Gilmour G; Dix S; Fellini L; Gastambide F; Plath N; Steckler T; Talpos J; Tricklebank M
    Neuropharmacology; 2012 Mar; 62(3):1401-12. PubMed ID: 21420987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.